{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:59:38Z","timestamp":1790643578497,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.vaccine.2012.12.050","type":"journal-article","created":{"date-parts":[[2012,12,31]],"date-time":"2012-12-31T20:48:01Z","timestamp":1356986881000},"page":"1019-1025","source":"Crossref","is-referenced-by-count":56,"title":["Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine"],"prefix":"10.1016","volume":"31","author":[{"given":"Irina","family":"Tretyakova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor S.","family":"Lukashevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Glass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eryu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pushko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"December (12)","key":"10.1016\/j.vaccine.2012.12.050_bib0005","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1586\/erv.09.132","article-title":"DNA vaccines for biodefense","volume":"8","author":"Dupuy","year":"2009","journal-title":"Expert Rev vaccines"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2012.12.050_bib0010","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1089\/hum.2006.17.1051","article-title":"DNA vaccines: recent developments and future possibilities","volume":"17","author":"Liu","year":"2006","journal-title":"Hum Gene Ther"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.12.050_bib0015","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0020","series-title":"Vaccines","author":"Plotkin","year":"2004"},{"issue":"April (2)","key":"10.1016\/j.vaccine.2012.12.050_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7589\/0090-3558-11.2.195","article-title":"Serologic evidence of Venezuelan equine encephalitis in some wild and domestic populations of southern Texas","volume":"11","author":"Smart","year":"1975","journal-title":"J Wildl Dis"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.12.050_bib0030","doi-asserted-by":"crossref","first-page":"441","DOI":"10.4269\/ajtmh.1999.60.441","article-title":"Genetic evidence for the origins of Venezuelan equine encephalitis virus subtype IAB outbreaks","volume":"60","author":"Weaver","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"October (41)","key":"10.1016\/j.vaccine.2012.12.050_bib0035","doi-asserted-by":"crossref","first-page":"7017","DOI":"10.1016\/j.vaccine.2007.07.030","article-title":"Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases","volume":"25","author":"Kitchen","year":"2007","journal-title":"Vaccine"},{"issue":"September (3)","key":"10.1016\/j.vaccine.2012.12.050_bib0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1128\/MMBR.58.3.491-562.1994","article-title":"The alphaviruses: gene expression, replication, and evolution","volume":"58","author":"Strauss","year":"1994","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1146\/annurev.ento.49.061802.123422","article-title":"Venezuelan equine encephalitis","volume":"49","author":"Weaver","year":"2004","journal-title":"Annu Rev Entomol"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0050","series-title":"Committee on a strategy for minimizing the impact of naturally occurring infectious diseases of military importance","article-title":"Protecting our forces: improving vaccine acquisition and availability in the U.S. military. Institute of Medicine (U.S.)","author":"Lemon","year":"2002"},{"issue":"November (Suppl. 4)","key":"10.1016\/j.vaccine.2012.12.050_bib0055","doi-asserted-by":"crossref","first-page":"D80","DOI":"10.1016\/j.vaccine.2009.07.095","article-title":"Vaccines for Venezuelan equine encephalitis","volume":"27","author":"Paessler","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0060","first-page":"209","article-title":"Attenuation of Venezuelan equine encephalomyelitis virus by in vitro cultivation in guinea-pig heart cells","volume":"73","author":"Berge","year":"1961","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/epirev\/mxj003","article-title":"Immunization to protect the US Armed Forces: heritage, current practice, and prospects","volume":"28","author":"Grabenstein","year":"2006","journal-title":"Epidemiol Rev"},{"issue":"April (Suppl. 4)","key":"10.1016\/j.vaccine.2012.12.050_bib0070","doi-asserted-by":"crossref","first-page":"92","DOI":"10.7205\/MILMED.170.4S.92","article-title":"History of U.S. military contributions to the study of viral encephalitis","volume":"170","author":"Hoke","year":"2005","journal-title":"Mil Med"},{"issue":"February (7\u20138)","key":"10.1016\/j.vaccine.2012.12.050_bib0075","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/S0264-410X(98)00315-6","article-title":"TC-83 vaccine protects against airborne or subcutaneous challenge with heterologous mouse-virulent strains of Venezuelan equine encephalitis virus","volume":"17","author":"Phillpotts","year":"1999","journal-title":"Vaccine"},{"issue":"March (4)","key":"10.1016\/j.vaccine.2012.12.050_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0264-410X(95)00168-Z","article-title":"Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine","volume":"14","author":"Pittman","year":"1996","journal-title":"Vaccine"},{"issue":"March (12)","key":"10.1016\/j.vaccine.2012.12.050_bib0085","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1016\/j.vaccine.2011.01.055","article-title":"Stability of RNA virus attenuation approaches","volume":"29","author":"Kenney","year":"2011","journal-title":"Vaccine"},{"issue":"September (38)","key":"10.1016\/j.vaccine.2012.12.050_bib0090","doi-asserted-by":"crossref","first-page":"16038","DOI":"10.1073\/pnas.1111650108","article-title":"Arbovirus high fidelity variant loses fitness in mosquitoes and mice","volume":"108","author":"Coffey","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"issue":"August (2)","key":"10.1016\/j.vaccine.2012.12.050_bib0095","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1006\/viro.1993.1421","article-title":"Diversity within natural populations of eastern equine encephalomyelitis virus","volume":"195","author":"Weaver","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0100","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4049\/jimmunol.87.5.509","article-title":"Studies on the virus of Venezuelan equine encephalomyelitis. II. Modification by specific immune serum of response of central nervous system of mice","volume":"November (87)","author":"Berge","year":"1961","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.vaccine.2012.12.050_bib0105","doi-asserted-by":"crossref","first-page":"e1486","DOI":"10.1371\/journal.pntd.0001486","article-title":"Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization","volume":"6","author":"Messer","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"issue":"March (6)","key":"10.1016\/j.vaccine.2012.12.050_bib0110","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1128\/JVI.80.6.2784-2796.2006","article-title":"Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN\/VEE viruses","volume":"80","author":"Paessler","year":"2006","journal-title":"J Virol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.12.050_bib0115","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1128\/JVI.67.3.1269-1277.1993","article-title":"Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5\u2032-noncoding region and the E2 envelope glycoprotein","volume":"67","author":"Kinney","year":"1993","journal-title":"J Virol"},{"issue":"March (3)","key":"10.1016\/j.vaccine.2012.12.050_bib0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.4269\/ajtmh.2005.72.330","article-title":"Venezuelan equine encephalitis virus in the guinea pig model: evidence for epizootic virulence determinants outside the E2 envelope glycoprotein gene","volume":"72","author":"Greene","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2012.12.050_bib0125","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.4269\/ajtmh.1982.31.1030","article-title":"Mesenteronal infection threshold of an epizootic strain of Venezuelan encephalitis virus in Culex (Melanoconion) taeniopus mosquitoes and its implication to the apparent disappearance of this virus strain from an enzootic habitat in Guatemala","volume":"31","author":"Scherer","year":"1982","journal-title":"Am J Trop Med Hyg"},{"issue":"August (31)","key":"10.1016\/j.vaccine.2012.12.050_bib0130","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1073\/pnas.0402905101","article-title":"Venezuelan equine encephalitis emergence: enhanced vector infection from a single amino acid substitution in the envelope glycoprotein","volume":"101","author":"Brault","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2012.12.050_bib0135","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4269\/ajtmh.2010.09-0556","article-title":"Vector competence of Culex (Melanoconion) taeniopus for equine-virulent subtype IE strains of Venezuelan equine encephalitis virus","volume":"82","author":"Deardorff","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2012.12.050_bib0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.4269\/ajtmh.1987.36.194","article-title":"Vector competence of Culex (Melanoconion) taeniopus for allopatric and epizootic Venezuelan equine encephalomyelitis viruses","volume":"36","author":"Scherer","year":"1987","journal-title":"Am J Trop Med Hyg"},{"issue":"March (9\u201310)","key":"10.1016\/j.vaccine.2012.12.050_bib0145","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0264-410X(98)00335-1","article-title":"Expression, processing, and immunogenicity of the structural proteins of Venezuelan equine encephalitis virus from recombinant baculovirus vectors","volume":"17","author":"Hodgson","year":"1999","journal-title":"Vaccine"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2012.12.050_bib0150","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jviromet.2009.11.006","article-title":"A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV)","volume":"163","author":"Fine","year":"2010","journal-title":"J Virol Methods"},{"issue":"April (18)","key":"10.1016\/j.vaccine.2012.12.050_bib0155","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2010.02.056","article-title":"Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"issue":"January (4)","key":"10.1016\/j.vaccine.2012.12.050_bib0160","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.vaccine.2009.10.126","article-title":"Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB","volume":"28","author":"Martin","year":"2010","journal-title":"Vaccine"},{"issue":"January (5)","key":"10.1016\/j.vaccine.2012.12.050_bib0165","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.vaccine.2010.11.033","article-title":"Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development","volume":"29","author":"Sharma","year":"2011","journal-title":"Vaccine"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2012.12.050_bib0170","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1128\/CVI.00030-11","article-title":"A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates","volume":"18","author":"Dupuy","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"October (46)","key":"10.1016\/j.vaccine.2012.12.050_bib0175","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1016\/j.vaccine.2010.09.005","article-title":"Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates","volume":"28","author":"Dupuy","year":"2010","journal-title":"Vaccine"},{"issue":"September (17)","key":"10.1016\/j.vaccine.2012.12.050_bib0180","doi-asserted-by":"crossref","first-page":"9278","DOI":"10.1128\/JVI.77.17.9278-9286.2003","article-title":"Recombinant sindbis\/Venezuelan equine encephalitis virus is highly attenuated and immunogenic","volume":"77","author":"Paessler","year":"2003","journal-title":"J Virol"},{"issue":"February (10)","key":"10.1016\/j.vaccine.2012.12.050_bib0185","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1016\/j.vaccine.2006.10.030","article-title":"Venezuelan equine encephalitis virus vaccine candidate (V3526) safety, immunogenicity and efficacy in horses","volume":"25","author":"Fine","year":"2007","journal-title":"Vaccine"},{"issue":"August (8)","key":"10.1016\/j.vaccine.2012.12.050_bib0190","article-title":"Host responses to live-attenuated Venezuelan equine encephalitis virus (TC-83): Comparison of naive, vaccine responder and nonresponder to TC-83 challenge in human peripheral blood mononuclear cells","volume":"8","author":"Erwin-Cohen","year":"2012","journal-title":"Hum vaccines immunother"},{"issue":"September (RR-12)","key":"10.1016\/j.vaccine.2012.12.050_bib0195","first-page":"1","article-title":"Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"45","year":"1996","journal-title":"MMWR"},{"issue":"November (9)","key":"10.1016\/j.vaccine.2012.12.050_bib0200","first-page":"1015","article-title":"Update on immunizations in adults","volume":"84","author":"Vaughn","year":"2011","journal-title":"Am Fam Physician"},{"issue":"September (1)","key":"10.1016\/j.vaccine.2012.12.050_bib0205","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1006\/viro.1995.1458","article-title":"Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site suppressor mutation in E1","volume":"212","author":"Davis","year":"1995","journal-title":"Virology"},{"issue":"July (1)","key":"10.1016\/j.vaccine.2012.12.050_bib0210","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0042-6822(89)90526-6","article-title":"In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant","volume":"171","author":"Davis","year":"1989","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0215","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1186\/1743-422X-8-356","article-title":"Infectious alphavirus production from a simple plasmid transfection+","volume":"8","author":"Steel","year":"2011","journal-title":"Virol J"},{"issue":"April (1)","key":"10.1016\/j.vaccine.2012.12.050_bib0220","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jviromet.2006.11.024","article-title":"An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials","volume":"141","author":"Surman","year":"2007","journal-title":"J Virol Methods"},{"issue":"November (4523)","key":"10.1016\/j.vaccine.2012.12.050_bib0225","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.6272391","article-title":"Cloned poliovirus complementary DNA is infectious in mammalian cells","volume":"214","author":"Racaniello","year":"1981","journal-title":"Science (New York, NY)"},{"issue":"September (18)","key":"10.1016\/j.vaccine.2012.12.050_bib0230","doi-asserted-by":"crossref","first-page":"10460","DOI":"10.1073\/pnas.1834270100","article-title":"DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus","volume":"100","author":"Hall","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2012.12.050_bib0235","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1177\/030098589803500508","article-title":"Comparative neurovirulence and tissue tropism of wild-type and attenuated strains of Venezuelan equine encephalitis virus administered by aerosol in C3H\/HeN and BALB\/c mice","volume":"35","author":"Steele","year":"1998","journal-title":"Vet Pathol"},{"issue":"May (25)","key":"10.1016\/j.vaccine.2012.12.050_bib0240","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2012.12.050_bib0245","series-title":"Medicinal protein engineering","first-page":"169","article-title":"Engineering better influenza vaccines: traditional and new approaches","author":"Pushko","year":"2009"},{"issue":"November\u2013December (6)","key":"10.1016\/j.vaccine.2012.12.050_bib0250","doi-asserted-by":"crossref","first-page":"453","DOI":"10.4161\/hv.4.6.6200","article-title":"Molecular and cellular mechanisms of DNA vaccines","volume":"4","author":"Coban","year":"2008","journal-title":"Human vaccines"},{"issue":"December (6)","key":"10.1016\/j.vaccine.2012.12.050_bib0255","doi-asserted-by":"crossref","first-page":"479","DOI":"10.2174\/156652311798192815","article-title":"Novel strategies to improve DNA vaccine immunogenicity","volume":"11","author":"Coban","year":"2011","journal-title":"Curr Gene Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2012.12.050_bib0260","doi-asserted-by":"crossref","first-page":"e34761","DOI":"10.1371\/journal.pone.0034761","article-title":"Modulation of GSK-3beta activity in Venezuelan equine encephalitis virus infection","volume":"7","author":"Kehn-Hall","year":"2012","journal-title":"PloS ONE"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12018373?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X12018373?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T09:00:28Z","timestamp":1687942828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X12018373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S0264410X12018373"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2012.12.050","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}